A xeno-transplantable plasma cell leukemia line with a split translocation of the IgH gene

Cancer Genetics and Cytogenetics

Volumn 144, Issue 1, 2003, Pages 31-35

  Ohbayashi, Kaneyuki ^a,d   Taniwaki, Masafumi ^b   Ninomiya, Manabu ^a   Kiyoi, Hitoshi ^a   Iida, Shinsuke ^c   Ueda, Ryuzo ^c   Naoe, Tomoki ^d  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^d ANJO KOSEI HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD19 ANTIGEN; CD38 ANTIGEN; CD56 ANTIGEN; CELL SURFACE MARKER; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; MELPHALAN; RANIMUSTINE; VINCRISTINE; VINDESINE;

ADULT; ANAMNESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW METASTASIS; CASE REPORT; CHROMOSOME 14Q; CHROMOSOME 20; CHROMOSOME 7P; CHROMOSOME XQ; CLINICAL FEATURE; CONTROLLED STUDY; CYTOGENETICS; CYTOLOGY; DIAGNOSTIC PROCEDURE; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE LOCUS; GENE TRANSLOCATION; HUMAN; HUMAN CELL; KARYOTYPE; LABORATORY TEST; LEUKEMIA CELL LINE; LIVER METASTASIS; MOUSE; NONHUMAN; ONCOGENE C MYC; PLASMA CELL; PLASMA CELL LEUKEMIA; PLASMACYTOSIS; PRIORITY JOURNAL; SPLEEN CANCER; STRUCTURAL CHROMOSOME ABERRATION; CANCER TRANSPLANTATION; CELL CULTURE; GENETICS; KARYOTYPING; MIDDLE AGED;

FEMALE; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LEUKEMIA, PLASMACYTIC; MIDDLE AGED; NEOPLASM TRANSPLANTATION; TRANSLOCATION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0038117777     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(02)00862-2     Document Type: Article

References (15)

1. Kyle R.A., Maldonado J.E., Bayrd E.D. Plasma cell leukemia. Report on 17 cases. Arch Intern Med. 133:1974;813-818.
2. Garcia-Sanz R., Orfao A., Gonzalez M., Tabernero M.D., Blade J., Moro M.J., Fernandez-Calvo J., Sanz M.A., Perez-Simon J.A., Rasillo A., Miguel J.F. Primary plasma cell leukemia. clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics Blood. 93:1999;1032-1037.
3. Nishida K., Tamura A., Nakazawa N., Ueda Y., Abe T., Matsuda F., Kashima K., Taniwaki M. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood. 90:1997;526-534.
4. Bergsagel P.L., Kuehl W.M. Chromosome translocations in multiple myeloma. Oncogene. 20:2001;5611-5622.
5. Avet-Loiseau H., Facon T., Grosbois B., Magrangeas F., Rapp M.J., Harousseau J.L., Minvielle S., Bataille R. Oncogenesis of multiple myeloma. 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation Blood. 99:2002;2185-2191.
6. Smadja N.V., Bastard C., Brgaudeau C. Primary plasma cell leukemia and multiple myeloma. one or two diseases according to the methodology Blood. 94:1999;3607-3609.
7. Hanamura I., Iida S., Akano Y., Hayami Y., Kato M., Miura K., Harada S., Banno S., Wakita A., Kiyoi H., Naoe T., Shimizu S., Sonta S.I., Nitta M., Taniwaki M., Ueda R. Ectopic expression of MAFB gene in human myeloma cells carrying (14;20)(q32;q11) chromosomal translocations. Jpn J Cancer Res. 92:2001;638-644.
8. Drexler H.G., Matsuo Y. Malignant hematopoietic cell lines. in vitro models for the study of multiple myeloma and plasma cell leukemia Leuk Res. 24:2000;681-703.
9. Yaccoby S., Epstein J. The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood. 94:1999;3576-3582.
10. Bergsagel P.L., Kuehl W.M. Multiple myeloma. Schechter G.P., Broudy V.C., Williams M.E. Hematology. 2001;157-163 The American Society of Hematology, Washington DC.
11. Sieweke M.H., Graf T. A transcription factor party during blood cell differentiation. Curr Biol. 8:1998;545-551.
12. Kim J.I., Ho I.C., Grusby M.J., Glimcher L.H. The transcription factor c-Maf controls the production of interleukin-4 but not other Th2 cytokines. Immunity. 10:1999;745-751.
13. Pellat-Deceunynck C., Barille S., Jego G., Puthier D., Robillard N., Pineau D., Rapp M.J., Harousseau J.L., Amiot M., Bataille R. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia. 12:1998;1977-1982.
14. Sahara N., Takeshita A., Shigeno K., Fujisawa S., Takeshita K., Naito K., Ihara M., Ono T., Tamashima S., Nara K., Ohnishi K., Ohno R. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. Br J Haematol. 117:2002;882-885.
15. Ely S.A., Knowles D.M. Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. Am J Pathol. 160:2002;1293-1299.